{"nctId":"NCT02174848","briefTitle":"Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration","startDateStruct":{"date":"2014-06"},"conditions":["Pantothenate Kinase-Associated Neurodegeneration"],"count":68,"armGroups":[{"label":"Deferiprone","type":"EXPERIMENTAL","interventionNames":["Drug: Deferiprone oral solution"]}],"interventions":[{"name":"Deferiprone oral solution","otherNames":["DFP"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completed study TIRCON2012V1\n\nExclusion Criteria:\n\n* Withdrew from the study TIRCON2012V1 for reasons of safety\n* Plan to participate in another clinical trial at any time from the day of enrolment until 30 days post-treatment in the current study","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":"Safety and tolerability were assessed based on changes in: frequency of adverse events (AEs), frequency of serious adverse events (SAEs), and discontinuation due to AEs. No statistical comparison between the groups was conducted as all participants received the same study product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Score on the BAD Scale -- Comparison of Treatment Groups Over Each Study","description":"The Barry-Albright Dystonia (BAD) scale is an instrument for rating the severity of dystonia in eight body regions. The individual scores are summed to provide a total score that ranges from 0 to 32; the higher the score, the more severe the dystonia. Patients were assessed for the change in total BAD score over the course of both the initial study (during which one group received placebo and the other received deferiprone) and the extension study (during which both groups received deferiprone).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"4.8"},{"groupId":"OG001","value":"1.9","spread":"3.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"3.7"},{"groupId":"OG001","value":"1.4","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Change in Score on the BAD Scale -- Comparison of Placebo-DFP Patients Across Studies","description":"The Barry-Albright Dystonia (BAD) scale is an instrument for rating the severity of dystonia in eight body regions. The individual scores are summed to provide a total score that ranges from 0 to 32; the higher the score, the more severe the dystonia. Patients were assessed for the change in total BAD score over the course of each study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"4.8"},{"groupId":"OG001","value":"1.4","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"Change in Score on the BAD Scale -- Comparison of DFP-DFP Patients Across Studies","description":"The Barry-Albright Dystonia (BAD) scale is an instrument for rating the severity of dystonia in eight body regions. The individual scores are summed to provide a total score that ranges from 0 to 32; the higher the score, the more severe the dystonia. Patients were assessed for the change in total BAD score over the course of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"3.2"},{"groupId":"OG001","value":"1.4","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Improved or Unchanged BAD Score","description":"Patients were deemed to be responders if their BAD total score either improved or remained unchanged from baseline, with baseline being the start of each study for the placebo-DFP group and the start of the initial study for the DFP-DFP group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Global Impression of Improvement (PGI-I) Comparison of Placebo-DFP Patients Across Studies","description":"The Patient Global Impression of Improvement (PGI-I) is a global index used to rate the response of a condition to a therapy. Patients were asked at each post-baseline visit to rate their overall condition since the start of the extension study on a 7-point rating scale: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"1.5"},{"groupId":"OG001","value":"4.7","spread":"1.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":33,"n":68},"commonTop":["Dystonia","Pyrexia","Headache","Serum ferritin decreased","Condition aggravated"]}}}